Resmetirom for NASH with Liver Fibrosis | NEJM
Journal Club: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
Promising Phase 3 Data for Resmetirom Suggests It May Address ‘Monumental’ Unmet Need in NASH
5-Minute Check In: Evaluating the Use of Resmetirom in Patients with NASH and Liver Fibrosis
FDA Approves First Drug for Non-Alcoholic Steatohepatitis (NASH): Resmetirom Explained │PHARMACOLOGY
Use of Biomarkers for Diagnosing and Assessing Treatment Response in Noncirrhotic NASH Trials-D1-AM
Leveraging Clinical Pharmacology to Optimize Drug Development for NASH & Cholestatic Liver Diseases2
Could New Drug Lower Cholesterol in lean people on a Keto diet?
2021-2022 NCSCG Webinar Series: Updates on NASH Therapeutics - Anything on the Horizon?
The Management of NASH: What does the future holds for us? by Naim Alkhouri, MD
NASH Animal Models and their Clinical Relevance – Quantitative Histopathology of Hepatic Fibrosis
108 - NASH Companies to Watch in 2022! Madrigal Pharma Announces Positive Data in NAFLD
Liso-cel for CLL/SLL, Tislelizumab for Esophageal SCC, Resmetirom for NASH, Maralixibat for...
Official Press Conference ILC 2022 - NAFLD (Friday, 24 June)
Update: NASH Abstracts from AASLD
EASL Studio S4E22 - JHEP Live: new and promising drugs for NASH on the horizon
2022 NCSCG Liver Symposium - Treating Nash in 2022
Gastroenterology Grand Rounds - January 20, 2022
S4-E34 - Drug Development Stories from EASL and ADA: Part 2
